Cassava Sciences Inc (NASDAQ:SAVA) CFO Eric Schoen acquired 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 14th. The shares were acquired at an average cost of $1.06 per share, for a total transaction of $10,600.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Shares of NASDAQ:SAVA traded up $0.02 during trading on Friday, reaching $1.09. The stock had a trading volume of 89,906 shares, compared to its average volume of 65,177. Cassava Sciences Inc has a 52 week low of $0.76 and a 52 week high of $10.80.
Cassava Sciences (NASDAQ:SAVA) last released its quarterly earnings results on Monday, April 29th. The company reported ($0.08) EPS for the quarter.
Cassava Sciences Company Profile
Cassava Sciences, Inc, a clinical-stage drug development company, develops drugs for nervous system disorders. The company's lead therapeutic product candidate PTI-125, a small molecule drug that is in Phase II clinical trial for the treatment of Alzheimer's disease. It is also developing PTI-125Dx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
Featured Article: Why do companies issue convertible shares?
Receive News & Ratings for Cassava Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cassava Sciences and related companies with MarketBeat.com's FREE daily email newsletter.